Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Medical Device

AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL

Fineline Cube Mar 3, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...

Company Drug

CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma

Fineline Cube Mar 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...

Policy / Regulatory

National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding

Fineline Cube Mar 3, 2023

The National Allied Procurement Office has released a notification regarding the Round 8 of the...

Company Deals

TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion

Fineline Cube Mar 3, 2023

China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly...

Company Drug

OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202

Fineline Cube Mar 3, 2023

Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...

Company Deals

Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy

Fineline Cube Mar 3, 2023

Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...

Company Deals

Shanghai Pharmaceuticals Partners with Baiyun District for Health Initiative

Fineline Cube Mar 3, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has entered into a strategic cooperation agreement...

Company Deals

TandemAI Secures $35M Series A to Expand Drug Discovery Platform

Fineline Cube Mar 3, 2023

TandemAI, a technology firm with operations in New York, San Diego, and China, has successfully...

Company Drug

Merck Reports 12.9% Sales Growth in 2022 Annual Report

Fineline Cube Mar 3, 2023

German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...

Policy / Regulatory

NHSA Releases Guidelines on Drug Procurement and Pricing Management

Fineline Cube Mar 2, 2023

The National Healthcare Security Administration (NHSA) has released a notification regarding provincial centralized procurement and...

Company Deals

Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib

Fineline Cube Mar 2, 2023

Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...

Company

Zai Lab Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 2, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...

Company Deals

Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development

Fineline Cube Mar 2, 2023

Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of...

Company Drug

Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study

Fineline Cube Mar 2, 2023

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...

Company Deals

Glowe Raises Series A+ Funding to Expand AIGC in Mental Health

Fineline Cube Mar 2, 2023

Glowe, an online psychological consultation platform based in Guangdong, has reportedly raised “tens of millions”...

Company Deals

Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production

Fineline Cube Mar 2, 2023

Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed...

Company Deals

Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development

Fineline Cube Mar 2, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...

Company Drug

CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia

Fineline Cube Mar 2, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...

Company Deals

BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results

Fineline Cube Mar 1, 2023

BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...

Company

Viatris Reports Q4 2022 Results, Highlights China Growth

Fineline Cube Mar 1, 2023

US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...

Posts pagination

1 … 574 575 576 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.